{"title":"接受激素治疗的乳腺癌患者与健康相关的生活质量研究综述","authors":"Lamya Alnaim","doi":"10.4274/ejbh.galenos.2022.2022-5-8","DOIUrl":null,"url":null,"abstract":"<p><p>This review aimed to analyze the significance and impact of health-related quality of life (QoL) in women with breast cancer undergoing treatment with hormonal therapy. This study developed a comprehensive, structured, systematic search strategy to identify literature related to health and QoL in breast cancer patients undergoing treatment with hormonal therapy. The search was conducted for published literature indexed in PubMed (Medline), Cancer Lit, CINAHL, Google Scholar, and Web of Science between 2010 and 2020. Patients associated with the study of QoL reported some difficulties in terms of depression, anxiety, chronic fatigue, sleep problems, pain, sexual dysfunction and sleep disorders. Endocrine-related symptoms did not fluctuate between interventions and remained unchanged in all groups. The evaluation of FACT-G scores (physical well-being subscale) showed statistically significant differences among participants receiving anastrozole versus tamoxifen and exemestane. It can be concluded that the QoL of postmenopausal women with breast cancer is affected by the long-term use of adjuvant endocrine therapy, with difference reported associated with the different therapies. However, further efforts are required to improve QoL instruments and the quantitative evaluation of QoL data for patients receiving adjuvant ET.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521283/pdf/ejbh-18-292.pdf","citationCount":"2","resultStr":"{\"title\":\"Health-Related Quality of Life in Women With Breast Cancer Undergoing Treatment With Hormonal Therapy - A Review Study.\",\"authors\":\"Lamya Alnaim\",\"doi\":\"10.4274/ejbh.galenos.2022.2022-5-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This review aimed to analyze the significance and impact of health-related quality of life (QoL) in women with breast cancer undergoing treatment with hormonal therapy. This study developed a comprehensive, structured, systematic search strategy to identify literature related to health and QoL in breast cancer patients undergoing treatment with hormonal therapy. The search was conducted for published literature indexed in PubMed (Medline), Cancer Lit, CINAHL, Google Scholar, and Web of Science between 2010 and 2020. Patients associated with the study of QoL reported some difficulties in terms of depression, anxiety, chronic fatigue, sleep problems, pain, sexual dysfunction and sleep disorders. Endocrine-related symptoms did not fluctuate between interventions and remained unchanged in all groups. The evaluation of FACT-G scores (physical well-being subscale) showed statistically significant differences among participants receiving anastrozole versus tamoxifen and exemestane. It can be concluded that the QoL of postmenopausal women with breast cancer is affected by the long-term use of adjuvant endocrine therapy, with difference reported associated with the different therapies. However, further efforts are required to improve QoL instruments and the quantitative evaluation of QoL data for patients receiving adjuvant ET.</p>\",\"PeriodicalId\":11885,\"journal\":{\"name\":\"European journal of breast health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521283/pdf/ejbh-18-292.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of breast health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/ejbh.galenos.2022.2022-5-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of breast health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/ejbh.galenos.2022.2022-5-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
本综述旨在分析接受激素治疗的乳腺癌患者健康相关生活质量(QoL)的意义和影响。本研究开发了一个全面的、结构化的、系统的搜索策略,以确定与接受激素治疗的乳腺癌患者的健康和生活质量相关的文献。该搜索是针对2010年至2020年间在PubMed (Medline)、Cancer Lit、CINAHL、Google Scholar和Web of Science上索引的已发表文献进行的。与生活质量研究相关的患者报告了一些困难,包括抑郁、焦虑、慢性疲劳、睡眠问题、疼痛、性功能障碍和睡眠障碍。内分泌相关症状在干预措施之间没有波动,并且在所有组中保持不变。FACT-G评分(身体健康量表)的评估显示,接受阿那曲唑与他莫昔芬和依西美坦治疗的参与者之间存在统计学上的显著差异。由此可见,长期使用辅助内分泌治疗对绝经后乳腺癌患者的生活质量有影响,不同的治疗方法有差异。然而,对于接受辅助ET治疗的患者,需要进一步努力改进生活质量仪器和生活质量数据的定量评估。
Health-Related Quality of Life in Women With Breast Cancer Undergoing Treatment With Hormonal Therapy - A Review Study.
This review aimed to analyze the significance and impact of health-related quality of life (QoL) in women with breast cancer undergoing treatment with hormonal therapy. This study developed a comprehensive, structured, systematic search strategy to identify literature related to health and QoL in breast cancer patients undergoing treatment with hormonal therapy. The search was conducted for published literature indexed in PubMed (Medline), Cancer Lit, CINAHL, Google Scholar, and Web of Science between 2010 and 2020. Patients associated with the study of QoL reported some difficulties in terms of depression, anxiety, chronic fatigue, sleep problems, pain, sexual dysfunction and sleep disorders. Endocrine-related symptoms did not fluctuate between interventions and remained unchanged in all groups. The evaluation of FACT-G scores (physical well-being subscale) showed statistically significant differences among participants receiving anastrozole versus tamoxifen and exemestane. It can be concluded that the QoL of postmenopausal women with breast cancer is affected by the long-term use of adjuvant endocrine therapy, with difference reported associated with the different therapies. However, further efforts are required to improve QoL instruments and the quantitative evaluation of QoL data for patients receiving adjuvant ET.